Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243320 · ClinicalTrials.gov registry record · Phase 1
In Vivo Assessment of Silver Biomaterial Nano-Toxicity
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01243320 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 36 participants.
The verdict
NCT01243320, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Nanotechnology is the controlled generation and manipulation of matter in dimensions less than 100 nm. Silver has been used for its bactericidal properties. The investigators propose to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human volunteers to determine the toxicity and to quantify cytochrome P450 enzyme effects of this solution.
Interventions
- DRUG 10ppm Oral Silver Particle
- DRUG 32ppm Oral Silver Particle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243320
The ClinicalTrials.gov registry entry for NCT01243320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 10ppm Oral Silver Particle is the first listed.
NCT01243320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243320 about?
NCT01243320 is a clinical study titled "In Vivo Assessment of Silver Biomaterial Nano-Toxicity". Nanotechnology is the controlled generation and manipulation of matter in dimensions less than 100 nm. Silver has been used for its bactericidal properties. The investigators propose to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human volunteers to determine...
What is the current status of trial NCT01243320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01243320?
The interventions under investigation include: 10ppm Oral Silver Particle (DRUG), 32ppm Oral Silver Particle (DRUG).
Who is sponsoring clinical trial NCT01243320?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.